Clinical Trial

Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema

Name: Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema — clinical trial record (NCT07429474)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-17.

Trial Details

NCT Number	NCT07429474
Lead Sponsor	Laboratorios Sophia S.A de C.V.
Conditions	Immunogenicity, Anti-drug Antibodies (ADAs)
Enrollment	60 participants
Start Date	2026-03-01
Primary Completion	2026-12-15 (estimated)
Study Completion	2026-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-13